Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure

Vuillerot C, Girardot F, Payan C, Fermanian J, Iwaz J, de Lattre C, Bérard C.
Dev med Child Neurol 2009. 52(1): 60-65.
Changes in MFM scores of 12 DMD patients treated with corticosteroids and 54 without treatment. The results support the use of MFM in the treatment of patients with Duchenne muscular dystrophy and its use in clinical trials to evaluate patients receiving a therapy. The MFM also help to predict the loss of walk for patients with DMD.

PubMed link

Keywords: Duchenne Muscular Dystrophy, MFM, Corticosteroids, Loss of walk, Management of patients

 

Articles dans les revues scientifiques

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932.  Protocol of the "SPACE" in wich MFM is used as an outcome measure....

read more